141 related articles for article (PubMed ID: 11145221)
1. The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds.
Aungst BJ; Nguyen NH; Bulgarelli JP; Oates-Lenz K
Pharm Res; 2000 Oct; 17(10):1175-80. PubMed ID: 11145221
[TBL] [Abstract][Full Text] [Related]
2. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD
AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145
[TBL] [Abstract][Full Text] [Related]
3. Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers.
Rouquayrol M; Gaucher B; Roche D; Greiner J; Vierling P
Pharm Res; 2002 Nov; 19(11):1704-12. PubMed ID: 12458677
[TBL] [Abstract][Full Text] [Related]
4. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
5. Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 cell monolayers.
Saha P; Kou JH
Eur J Pharm Biopharm; 2000 Nov; 50(3):403-11. PubMed ID: 11072198
[TBL] [Abstract][Full Text] [Related]
6. Transport characteristics of peptidomimetics. Effect of the pyrrolinone bioisostere on transport across Caco-2 cell monolayers.
Sudoh M; Pauletti GM; Yao W; Moser W; Yokoyama A; Pasternak A; Sprengeler PA; Smith AB; Hirschmann R; Borchardt RT
Pharm Res; 1998 May; 15(5):719-25. PubMed ID: 9619780
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein effects of cyclic urea HIV protease inhibitor DMP 323 in competitional absorption studies.
Richter M; Gyémánt N; Molnár J; Hilgeroth A
Arch Pharm (Weinheim); 2006 Nov; 339(11):625-8. PubMed ID: 17048292
[TBL] [Abstract][Full Text] [Related]
8. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.
Alsenz J; Steffen H; Alex R
Pharm Res; 1998 Mar; 15(3):423-8. PubMed ID: 9563072
[TBL] [Abstract][Full Text] [Related]
9. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.
Hodge CN; Aldrich PE; Bacheler LT; Chang CH; Eyermann CJ; Garber S; Grubb M; Jackson DA; Jadhav PK; Korant B; Lam PY; Maurin MB; Meek JL; Otto MJ; Rayner MM; Reid C; Sharpe TR; Shum L; Winslow DL; Erickson-Viitanen S
Chem Biol; 1996 Apr; 3(4):301-14. PubMed ID: 8807858
[TBL] [Abstract][Full Text] [Related]
10. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
Kim RB; Fromm MF; Wandel C; Leake B; Wood AJ; Roden DM; Wilkinson GR
J Clin Invest; 1998 Jan; 101(2):289-94. PubMed ID: 9435299
[TBL] [Abstract][Full Text] [Related]
11. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
12. Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model.
Kapitza SB; Michel BR; van Hoogevest P; Leigh ML; Imanidis G
Eur J Pharm Biopharm; 2007 Apr; 66(1):146-58. PubMed ID: 17071065
[TBL] [Abstract][Full Text] [Related]
13. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport.
Hilgendorf C; Spahn-Langguth H; Regårdh CG; Lipka E; Amidon GL; Langguth P
J Pharm Sci; 2000 Jan; 89(1):63-75. PubMed ID: 10664539
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
[TBL] [Abstract][Full Text] [Related]
15. Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2.
Krishna G; Chen K; Lin C; Nomeir AA
Int J Pharm; 2001 Jul; 222(1):77-89. PubMed ID: 11404034
[TBL] [Abstract][Full Text] [Related]
16. Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice.
Holmstock N; Annaert P; Augustijns P
Drug Metab Dispos; 2012 Aug; 40(8):1473-7. PubMed ID: 22550269
[TBL] [Abstract][Full Text] [Related]
17. The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir but not indinavir impair the epithelial barrier in the human intestinal cell line HT-29/B6.
Bode H; Schmidt W; Schulzke JD; Fromm M; Zippel T; Wahnschaffe U; Bendfeldt K; Riecken EO; Ullrich R
AIDS; 1999 Dec; 13(18):2595-7. PubMed ID: 10630532
[No Abstract] [Full Text] [Related]
18. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
Kuschak D; Mauss S; Schmutz G; Gantke B
Clin Lab; 2001; 47(9-10):471-7. PubMed ID: 11596909
[TBL] [Abstract][Full Text] [Related]
20. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4.
Hochman JH; Chiba M; Nishime J; Yamazaki M; Lin JH
J Pharmacol Exp Ther; 2000 Jan; 292(1):310-8. PubMed ID: 10604964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
